Skip to main content
WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
36.62
+1.20 (3.39%)
Mar 10, 2026, 4:08 PM HKT

WuXi Biologics Revenue

WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.

Revenue (ttm)
20.05B CNY
Revenue Growth
+17.16%
P/S Ratio
6.67
Revenue / Employee
1.60M CNY
Employees
12,552
Market Cap
146.55B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 202418.68B1.64B9.63%
Dec 31, 202317.03B1.77B11.56%
Dec 31, 202215.27B4.98B48.38%
Dec 31, 202110.29B4.68B83.35%
Dec 31, 20205.61B1.63B40.88%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Innovent Biologics 12.52B
Sino Biopharmaceutical 33.49B
Akeso 2.75B
Sichuan Kelun-Biotech Biopharmaceutical 1.64B
BeOne Medicines AG 41.59B
RemeGen 3.62B
3SBio 9.94B
Shanghai Henlius Biotech 6.35B
Revenue Rankings

WuXi Biologics News

More News